Hepion Pharmaceuticals, Inc. (HEPA) Cash Flow Statement

The extreme volatility in the conversion of net losses to cash burn suggests that non-cash items and working capital swings are the primary drivers of reported figures rather than operational performance. Investors should interpret this disconnect as a sign that the company's cash position is highly sensitive to accounting adjustments and timing differences rather than sustainable business activity.

The persistent negative FCF trajectory indicates that the firm is consuming its remaining capital at a rate that threatens its ability to reach the next clinical milestone. This trend suggests that the company is in a terminal phase of its current funding cycle, necessitating a strategic pivot or capital raise that may be highly dilutive to existing shareholders.

The reliance on working capital fluctuations to manage cash flow suggests that the company is likely deferring payments or managing payables aggressively to extend its limited runway. This behavior warrants further investigation, as it may indicate that the firm is nearing the limits of its ability to manage liquidity through operational adjustments alone.